The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 14, 2021

Filed:

Mar. 24, 2017
Applicants:

The Broad Institute, Inc., Cambridge, MA (US);

Massachusetts Institute of Technology, Cambridge, MA (US);

The General Hospital Corporation, Boston, MA (US);

Inventors:

Aviv Regev, Cambridge, MA (US);

Oren Parnas, Jerusalem, IL;

Marko Jovanovic, Boston, MA (US);

Nir Hacohen, Brookline, MA (US);

Thomas Eisenhaure, North Reading, MA (US);

Assignees:

The Broad Institute, Inc., Cambridge, MA (US);

Massachusetts Institute of Technology, Cambridge, MA (US);

The General Hospital Corporation, Boston, MA (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A01K 67/027 (2006.01); C12N 15/63 (2006.01); C12N 15/79 (2006.01); C07H 21/02 (2006.01); C12N 15/113 (2010.01); C12N 15/11 (2006.01); A61K 48/00 (2006.01); C12N 7/04 (2006.01); C12N 9/22 (2006.01); C12N 15/10 (2006.01); C12N 15/85 (2006.01); C12N 15/90 (2006.01);
U.S. Cl.
CPC ...
A01K 67/0271 (2013.01); A01K 67/0275 (2013.01); A61K 48/005 (2013.01); C12N 7/04 (2013.01); C12N 9/22 (2013.01); C12N 15/1082 (2013.01); C12N 15/111 (2013.01); C12N 15/113 (2013.01); C12N 15/85 (2013.01); C12N 15/907 (2013.01); A01K 2207/05 (2013.01); A01K 2207/12 (2013.01); A01K 2217/052 (2013.01); A01K 2217/077 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0312 (2013.01); A01K 2267/0331 (2013.01); A01K 2267/0362 (2013.01); C07K 2319/09 (2013.01); C12N 2310/10 (2013.01); C12N 2310/20 (2017.05); C12N 2310/3513 (2013.01); C12N 2310/531 (2013.01); C12N 2320/12 (2013.01); C12N 2330/31 (2013.01); C12N 2330/51 (2013.01); C12N 2740/15043 (2013.01); C12N 2750/14143 (2013.01);
Abstract

The invention involves a method for modulating leukocyte activity, comprising delivering to a leukocyte a vector containing nucleic acid molecule(s), whereby the leukocyte contains Cas9 and the vector expresses one or more RNAs to guide the Cas9 to introduce mutations in one or more target genetic loci in the leukocyte, thereby modulating expression of one or more genes expressed in the leukocyte. The invention also involves identifying genes associated with leukocyte responses and experimental modeling of aberrant leukocyte activation and diseases associated with leukocytes by introducing mutations into leukocytes. The invention comprehends testing putative treatments with such models, e.g., testing putative chemical compounds that may be pharmaceutically relevant for treatment or gene therapy that may be relevant for treatment, or combinations thereof. The invention allows for the study of genetic diseases and putative treatments to better understand and alleviate leukocyte associated diseases.


Find Patent Forward Citations

Loading…